We developed a retrovirus-based protein-fragment complementation assay (RePCA) screen to identify protein-protein interactions in mammalian cells. In RePCA, bait protein is fused to one fragment of a rationally dissected fluorescent protein, such as GFP, intensely fluorescent protein, or red fluorescent protein. The second, complementary fragment of the fluorescent protein is fused to an endogenous protein by in-frame exon traps in the enhanced retroviral mutagen vector. An interaction between bait and host protein (prey) places the two parts of the fluorescent molecule in proximity, resulting in reconstitution of fluorescence. By using RePCA, we identified a series of 24 potential interaction partners or substrates of the serine͞threonine protein kinase AKT1. We confirm that ␣-actinin 4 (ACTN4) interacts physically and functionally with AKT1. siRNA-mediated ACTN4 silencing down-regulates AKT phosphorylation, blocks AKT translocation to the membrane, increases p27 Kip1 levels, and inhibits cell proliferation. Thus, ACTN4 is a critical regulator of AKT1 localization and function.
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␣-actinin 4 ͉ AKT1 ͉ protein-protein interactions ͉ screen P resently, novel protein-protein interactions are identified by using yeast two-hybrid (Y2H) systems (1), coimmunoprecipitation (Co-IP) and mass spectrometry (2) , or protein libraries (3) . These approaches, however, do not efficiently identify protein interactions on the cytoskeleton or membrane, either because of the location of the interaction (Y2H) or difficulties in the Co-IP of cytoskeletal or membrane proteins. Furthermore, conventional Y2H approaches yield false-positive signals with transcription factors precluding screening. The purpose of this study was to develop a readily applicable, subcellular localization-, library-, and cellindependent method for the identification of protein-protein interactions, including cytoskeletal and membrane proteins, in mammalian cells and apply it to the well characterized AKT protooncogene.
The retrovirus-based protein-fragment complementation assay (RePCA) utilizes the technical advantages of two emerging technologies, the enhanced retroviral mutagen (ERM) vector and the protein-fragment complementation assay (PCA). The ERM vector functions as an exon trap that efficiently activates and tags endogenous genes (4) . The ERM vector in all three ORFs can be applied to any mammalian cell without the effort and bias of cell-specific libraries. Furthermore, the ERM vector utilizes the endogenous splicing machinery of the target cell, allowing the evaluation of variations in natural splice variants. In PCA, a reporter protein, such as a monomeric enzyme or a fluorescent protein (GFP or a variant thereof), is rationally dissected into two fragments that will not reconstitute spontaneously (5) (6) (7) . When each fragment of the fluorescent protein is fused to one of a pair of interacting protein partners, the subsequent protein binding places the fragments in proximity, creating a functional complex that restores fluorescence levels to near that of the parental molecule (8) . Recently, Remy and Michnick (9) identified an AKT1 partner with a PCA-based cDNA library screen using GFP as a reporter. However, the need to generate cell-specific cDNA libraries and a complex approach to the identification of candidates renders this approach technically demanding and labor-intensive. RePCA combines the power of ERM (4) with PCA (8) to provide a facile, sensitive approach for the identification of context-dependent protein-protein interactions in mammalian cells, allowing native protein folding and posttranslational modifications.
Results
RePCA Screen Design. The intensely fluorescent protein (IFP), also known as Venus (10), was dissected into two fragments, an IFP N-terminal portion (IFPN) and IFP C-terminal portion (IFPC), at residue 158 (11) . As shown in Fig. 1A , IFPC was inserted into the ERM vector, followed by a splice donor, to construct the RePCA vector. A Tet-responsive promoter obviates potential toxicity of the fusion protein. After infection of the target cells, the retrovirus undergoes reverse transcription and integration into the host genome. If the integration occurs upstream or inside a host gene, the splice donor in the RePCA vector generates a fusion transcript with IFPC linked in-frame to downstream host exons. The propensity of the ERM retrovirus to integrate near the start of transcriptional units increases the chance that a full-length or near-full-length fusion protein will be created (12) .
A host cell line expressing the tetracycline-regulated transactivator tTA or reverse tTA to enable the regulated expression of the prey from the Tet-responsive promoter is generated by transfection to express the IFPN-Bait fusion protein (Fig. 1B) . Bait fusion protein-expressing cells are infected with the RePCA retrovirus in all three frames to generate in-frame IFPC-endogenous fusion proteins. Cells in which the retrovirus does not generate an in-frame fusion protein or wherein IFPC is not fused to a binding partner of the bait do not fluoresce. Only cells containing IFPC fused in-frame to an interaction partner of the bait fluoresce. The fluorescent cells are cloned, and the target genes are identified by RT-PCR with primers contained in the ERM vector. The resulting fluorescent clones can be directly used to characterize the formation, localization, and functionality of candidate interactions, providing powerful reagents for mechanistic exploration without the need for recloning.
known AKT partner, phosphoinositide-dependent kinase 1 (PDK1)-IFPC (15), into IFPN-AKT1 HeLa Tet-on cells resulted in fluorescence, which was enriched in the cell membrane and at points of cell-cell contact ( Fig. 2A) . The membrane localization of the PDK1-IFPC:IFPN-AKT1 complex was completely blocked by inhibition of phosphatidylinositol 3 kinase (PI3K) with LY294002, as expected from the known localization of AKT1 and PDK1 (16, 17) . Thus, linking each part of IFP to interacting proteins AKT1 and PDK1 reconstitutes IFP fluorescence with appropriate subcellular localization.
IFPN-AKT1 HeLa Tet-on cells were separately infected with RePCA-IFPC retroviral vectors in all three reading frames. After selection with puromycin and induction with doxycycline, single fluorescent cells were isolated by sorting. Expanded clones displayed fluorescence with different patterns, i.e., homogenous, cytoplasmic, nuclear, or membrane, suggesting differential localization of AKT1 and specific binding partners (see Fig. 2 B-D and Table 1 ). We chose 70 fluorescent clones for identification of target genes (10, 30 , and 30 clones for reading frame 1, 2, and 3, respectively), all of which yielded fusion transcripts. In terms of efficiency, using frame 2 as an example, 2 ϫ 10 7 cells were sorted, with the 384 most highly fluorescent cells placed in single wells. Doxycycline was withdrawn to reduce the expression of proteins that could have adverse effects on cell survival and growth. Of the 384 cells sorted, 120 cells (Ϸ30%) formed colonies, with 55 colonies showing fluorescence after doxycycline induction (Ϸ14%). We chose 30 clones based on fluorescence intensity and patterns and identified 11 independent candidate AKT1 partners (Table 1) . Thus, from 2 ϫ 10 7 cells, 11 candidates were identified. This pilot screen was not taken to saturation; therefore, it is likely that additional AKT1-binding partners would be identified in largescale screens. Twenty-four independent candidates were identified from all three ORFs (Table 1) . Some candidates were present as multiple clones [i.e., BCL2-antagonist of cell death (BAD) was identified three times (Table 1) ] and were likely derived from a single infected parental cell that divided before cell sorting, because sequencing demonstrated identical fusion transcripts. Limiting cell propagation before sorting fluorescent cells could increase the target diversity identified in the screen. IFPC fusion proteins similar to calculated sizes were detected in all clones (see Fig. 5 , which is published as supporting information on the PNAS web site, for selected clones) except for AHNAK2, which has an expected molecular weight of Ͼ600 kDa, precluding detection by Western blots. The identification of AHNAK2 demonstrates the power of the ERM vector, which, through the use of endogenous splicing machinery, is not restricted in terms of size of insert. In 14 of 24 clones, the IFPC fragment was fused to a full-length or near-fulllength protein (Table 1) . Among the targets, BAD is a well characterized AKT substrate and interaction partner (18) . Myosin light chain (atrial͞embryonic alkali) (MYL4) is part of the myosin II complex, a known AKTbinding partner (19) . AHA1, Annexin1, and a Lamin A͞C isoform (LaminB1) have been confirmed as AKT-binding partners by Co-IP and mass spectroscopy (J. Downward, personal communication). We also identified two potential AKT substrates because heme oxygenase 2 (HMOX2) and C14ORF78 (AHNAK2) are isoforms of HMOX1 and AHNAK1, which are known AKT substrates (20, 21) . Additional candidates have strong links to AKT (Table 1) . For example, CD98 regulates AKT phosphorylation and activation (22) . Both CD98 and AKT interact with integrin-␤1 (22, 23) . Moesin and AKT interact with the hamartin:tuberin complex (24-26). The identification of known and likely AKT partners͞ substrates validates the screening strategy.
␣-Actinin 4 (ACTN4) Is a Functional Partner of AKT1. ␣-Actinin actin-binding proteins, including ACTN4, can bind the p85 regulatory subunit of PI3K and translocate out of the membrane after inhibition of PI3K (27) (28) (29) . In addition, ACTN4 contributes to the prognosis of breast cancer (29) and has been implicated in tumor development, invasion, and metastases (30, 31), making it a candidate for further characterization. The fluorescence of the ACTN4 clone (IC1-05) obtained from the screen was markedly increased by doxycycline; therefore, formation of the fluorescent complex was controlled by Tet-responsive expression of the IFPC fusion protein (Fig. 3A) . The fluorescent IFPN-AKT1::IFPC-ACTN4 complex in clone IC1-05 was located throughout the cytoplasm in serumstarved cells (Fig. 3B) . Serum induced the translocation of the AKT1::ACTN4 complex to the membrane, in particular cellular ruffles, reminiscent of the PDK1::AKT1 complex (Fig. 2 A) , and to the nuclear periphery (Fig. 3B) . Compatible with the observation that ACTN4 translocates out of the membrane upon inhibition of PI3K (29) , serum-dependent translocation of the AKT1::ACTN4 complex to the cell membrane was blocked by inhibition of PI3K, indicating that membrane localization depended on the production of 3-phosphorylated membrane phosphatidylinositols. Expression of an exogenous IFPC-ACTN4wt in IFPN-AKT1 HeLa Tet-on cells resulted in fluorescence, which was enriched at the leading edge of cells growing in serum (Fig. 3C) , confirming that the apparent interaction between ACTN4 and AKT1 was not due to clonal variation. Expression of a IFPC-ACTN4⌬310-665 deletion construct resulted in homogeneous fluorescence in the cytoplasm with enhanced fluorescence in the nucleus but completely failed to Accession nos. and gene symbols are from GenBank. *Known partners͞substrates or potential partners͞substrates with known links to AKT. † RTN4 has five splice variants, A-E, with the same C-terminal sequence. The insertion site for RTN4 was defined according to the RTN4 variant C sequence. ‡ Potential AKT partners͞substrates without obvious known links to AKT.
mediate localization of the fluorescent complex to the leading edge of cells growing in serum (Fig. 3C) . In contrast, coexpression of IFPN-AKT1 and IFPC-ACTN4⌬310-911 did not result in detectable fluorescence (Fig. 3C) . Thus, residues 665-911 of ACTN4, which contain two EF motifs, are required for the interaction with AKT1, whereas residues 310-665 of ACTN4 are critical for the localization of the AKT1::ACTN4 complex to the leading edge of cells. Strikingly, the PH domain of AKT1 (32) was not sufficient to translocate the AKT1::ACTN4 complex to the cell membrane, suggesting that ACTN4 contributes to AKT1 localization. However, given that LY294002 blocked translocation (Fig. 3B) , the translocation of the AKT1::ACTN4 complex to the membrane depends on the production of 3-phosphorylated membrane phosphatidylinositols. Therefore, the screening approach not only provides insight into the binding partners of AKT1, but the resultant cells can also provide important functional information related to the localization and formation of the protein complexes. In clone IC1-05, IFPC-ACTN4 was readily immunoprecipitated by anti-AKT1 antibodies and detected by immunoblotting with a polyclonal anti-GFP antibody, which binds both halves of IFP (Fig.  3D) . Equal amounts of IFPC-ACTN4 and IFPC-AKT1 were present in the immunoprecipitated complex, compatible with the formation of a dimer. In parental HeLa Tet-on cells, ACTN4 could be immunoprecipitated by anti-AKT1 antibodies after in vivo cross-linking ( Fig. 3E ; see also Supporting Materials and Methods, which is published as supporting information on the PNAS web site), demonstrating an association of endogenous AKT1 with ACTN4. We were unable to detect a stable association between endogenous AKT1 and ACTN4 by Co-IP in the absence of cross-linking (data not shown), potentially because the conditions required to efficiently release ACTN4 from the cytoskeleton disrupted interactions between AKT1 and ACTN4 or because the interaction between AKT1 and ACTN4 was transient or indirect. (13, 14) . The distinctive pattern of ACTN4::AKT1 complex localization suggested that ACTN4 could contribute to AKT translocation and, thus, activation. In HeLa Tet-on cells as well as in IOSE80-hTERT (hTERT, human telomerase reverse transcriptase) cells not expressing exogenous AKT or ACTN4 IFP fusion proteins (Fig. 4A) , an siRNA pool targeting ACTN4 induced a concordant reduction in ACTN4 protein expression and AKT phosphorylation. Strikingly, ACTN4 silencing increased levels of the cyclin-dependent kinase inhibitor p27
Kip1 protein (Fig. 4A) , a known downstream target of AKT (33) . Additional siRNA constructs inhibited AKT phosphorylation, with ACTN4 knockdown and pAKT phosphorylation being concordant (Fig. 6 , which is published as supporting information on the PNAS web site). Insulin induced translocation of AKT1 fused to a full-length GFP protein (in parental HeLa cells not expressing AKT or ACTN4 fusion proteins) to the cell membrane, which was blocked by ACTN4 siRNA knockdown, confirming a role for ACTN4 in the translocation of AKT1 to the membrane (Fig. 4B) . The effects of ACTN4 knockdown on the phosphorylation of HA-AKT1 were bypassed by membrane-targeted myristylated AKT1 (Fig. 4C) , indicating that ACTN4 knockdown prevents translocation of AKT1 to the cell membrane. ACTN4 knockdown did not markedly alter F-actin in HeLa cells, suggesting that the effects of ACTN4 siRNA were not secondary to the disruption of the cellular cytoskeleton (Fig. 4D) . Finally, knockdown of ACTN4 significantly inhibited HeLa cell proliferation (Fig. 4E) , with different siRNAs demonstrating similar activity on ACTN4 knockdown, decrease in AKT phosphorylation (Fig. 6) , and cell proliferation. Thus, ACTN4 plays an essential role in AKT translocation, activation, signaling, and function, which demonstrates the ability of RePCA to uncover functional protein-protein interactions. 
Discussion
The identification of known and likely AKT1-binding partners and substrates (Table 1) validated RePCA as being able to identify protein-protein interactions and potentially transient interactions between enzyme and substrate in mammalian cells. A previously uncharacterized physical and functional interaction was identified between ACTN4 and AKT1. Functional association was demonstrated by siRNA-mediated ACTN4 silencing, which inhibits AKT translocation and phosphorylation, resulting in up-regulation of p27 Kip1 protein and a decrease in cell proliferation. An interaction between ACTN4 and AKT may underlie the pathophysiology of focal segmental glomerulosclerosis, which is caused by ACTN4 mutations (34), suggesting novel therapeutic approaches. ACTN4 also associates with focal adhesions, tight junctions, and adherens junctions through interactions with the cytoskeleton and the tightjunction protein MAGI-1 (35) , linking the PI3K͞AKT pathway to motility and invasion.
RePCA has a number of potential advantages. interacting partners and the creation of pathways and networks based on protein-protein interactions. (ix) RePCA can identify interactions in multiple different intracellular compartments, particularly cytoskeletal, membrane, and transcription-factor interactions , that are difficult to discover by using a Y2H or mass spectrometry approach. (x) Molecular interactions are detected directly, not through secondary events, such as transcription activation.
The RePCA approach has a number of potential limitations. Identification of Target Genes. Total RNA was extracted from expanded clones by using RNeasy Mini kits (Qiagen, Valencia, CA). Reverse transcription was performed with a random primer RT-1 (5Ј-GCAAATACGACTCACTATAGGGATCCNNNN-(GC)ACG-3Ј; n ϭ AGCT) (4), or a PolyT primer RT-1T (5Ј-GCAAATACGACTCACTATAGGGATCCTTTTTTTTT-TTTTTTT-3Ј) using a SuperScript III kit (Invitrogen, Carlsbad, CA). The 5Ј end of the RT-1 primer contains the T7 primer sequence. The cDNA was PCR-amplified with a specific IFPC primer (IFPCR, 5Ј-ACTTCAAGATCCGCCACAACATCGAG-3Ј) and the T7 primer (T7-2, 5Ј-GCAAATACGACTCACTAT-AGGGATC-3Ј) by using AccuTaq DNA polymerase (Invitrogen). Gel-purified PCR products were directly sequenced, with the resulting sequences used to search GenBank human nonredundant and expressed-sequence-tag databases by using BLAST.
RNAi and Cell Growth Assay. A pool of four siRNAs targeting human ACTN4 and a nontargeting siRNA pool were from Dharmacon (Lafayette, CO). Two single siRNAs targeting human ACTN4 were from Ambion (Austin, TX). RNAi silencing was performed according to the manufacturer's protocol. The effects of siRNA knockdown on cell growth was assessed by a 3,(4,5-dimethylthiazol-2-yl)2,5-diphenyltetrazolium bromide assay (40) .
